CRISM Therapeutics Corporation Total Assets
CRISM Therapeutics Corporation total assets. Based on the latest financial reports, CRISM Therapeutics Corporation (CRTX) holds total assets worth GBX2.92 Million GBX (≈ $355.52 USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see CRTX company net worth for the company's overall valuation and market capitalisation.
Total Assets of CRISM Therapeutics Corporation (2006–2025)
Total assets of CRISM Therapeutics Corporation from 2006 to 2025. This chart illustrates how CRISM Therapeutics Corporation's total assets have evolved over time, based on quarterly financial data. See CRTX stock price for real-time trading data and today's change.
CRISM Therapeutics Corporation - Asset Composition Analysis
CRISM Therapeutics Corporation Total Assets Breakdown (December 2025)
CRISM Therapeutics Corporation total assets breakdown as of December 2025. CRISM Therapeutics Corporation's total assets of GBX2.92 Million consist of 92.2% current assets and 7.8% non-current assets.
| Asset Category | Amount (GBX) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 62.8% |
| Accounts Receivable | GBX242.00K | 13.5% |
| Inventory | GBX0.00 | 0.0% |
| Property, Plant & Equipment | GBX0.00 | 0.0% |
| Intangible Assets | GBX104.00K | 5.8% |
| Goodwill | GBX0.00 | 0.0% |
Asset Composition Trend (2006–2025)
This chart illustrates how CRISM Therapeutics Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital to net assets of CRISM Therapeutics Corporation to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CRISM Therapeutics Corporation's current assets represent 92.2% of total assets in 2025, an increase from 32.8% in 2006.
- Cash Position: Cash and equivalents constituted 62.8% of total assets in 2025, up from 32.1% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, a decrease from 67.0% in 2006.
- Asset Diversification: The largest asset category is accounts receivable at 13.5% of total assets.
CRISM Therapeutics Corporation Competitors by Total Assets
Key competitors of CRISM Therapeutics Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.88 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥725.73 Million |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
|
China | CN¥3.67 Billion |
CRISM Therapeutics Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.10 | 3.65 | 2.74 |
| Quick Ratio | 8.10 | 3.65 | 2.49 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | GBX2.44 Million | GBX1.13 Million | GBX1.45 Million |
CRISM Therapeutics Corporation - Advanced Valuation Insights
This section examines the relationship between CRISM Therapeutics Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.99 |
| Latest Market Cap to Assets Ratio | 0.05 |
| Asset Growth Rate (YoY) | -1.0% |
| Total Assets | GBX1.80 Million |
| Market Capitalization | $84.30K USD |
Valuation Analysis
Below Book Valuation: The market values CRISM Therapeutics Corporation's assets below their book value (0.05x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: CRISM Therapeutics Corporation's assets decreased by 1.0% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for CRISM Therapeutics Corporation (2006–2025)
The table below shows the annual total assets of CRISM Therapeutics Corporation from 2006 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | GBX1.80 Million ≈ $218.64 |
-1.05% |
| 2024-12-31 | GBX1.82 Million ≈ $220.95 |
+1031.27% |
| 2023-12-31 | GBX160.53K ≈ $19.53 |
-99.33% |
| 2022-12-31 | GBX23.89 Million ≈ $2.91K |
-23.51% |
| 2021-12-31 | GBX31.24 Million ≈ $3.80K |
-3.60% |
| 2020-12-31 | GBX32.40 Million ≈ $3.94K |
+51.87% |
| 2019-12-31 | GBX21.34 Million ≈ $2.60K |
-18.69% |
| 2018-12-31 | GBX26.24 Million ≈ $3.19K |
-9.96% |
| 2017-12-31 | GBX29.14 Million ≈ $3.55K |
-0.96% |
| 2016-12-31 | GBX29.43 Million ≈ $3.58K |
+84.90% |
| 2015-12-31 | GBX15.91 Million ≈ $1.94K |
-24.67% |
| 2014-12-31 | GBX21.12 Million ≈ $2.57K |
+16.54% |
| 2013-12-31 | GBX18.13 Million ≈ $2.21K |
+11.96% |
| 2012-12-31 | GBX16.19 Million ≈ $1.97K |
-23.95% |
| 2011-12-31 | GBX21.29 Million ≈ $2.59K |
-0.52% |
| 2010-12-31 | GBX21.40 Million ≈ $2.60K |
+27.31% |
| 2009-12-31 | GBX16.81 Million ≈ $2.05K |
+51.79% |
| 2008-12-31 | GBX11.07 Million ≈ $1.35K |
+65.05% |
| 2007-12-31 | GBX6.71 Million ≈ $816.36 |
-28.22% |
| 2006-12-31 | GBX9.35 Million ≈ $1.14K |
-- |
About CRISM Therapeutics Corporation
CRISM Therapeutics Corporation develops a drug delivery technology for the clinical performance of cancer treatments for solid tumors through the local delivery of chemotherapy drugs in the British Virgin Islands. The company's lead product is ChemoSeed, which can be implanted directly into the tumour or the resection margin following the removal of a tumour. It also provides formulation and cons… Read more